AdvisorShares Investments LLC Decreases Stake in Jazz Pharmaceuticals PLC $JAZZ

AdvisorShares Investments LLC reduced its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 50.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,140 shares of the specialty pharmaceutical company’s stock after selling 5,200 shares during the period. AdvisorShares Investments LLC’s holdings in Jazz Pharmaceuticals were worth $677,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of JAZZ. Farther Finance Advisors LLC lifted its position in Jazz Pharmaceuticals by 754.8% during the third quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock valued at $35,000 after purchasing an additional 234 shares during the period. Hantz Financial Services Inc. raised its stake in shares of Jazz Pharmaceuticals by 471.4% during the 2nd quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock worth $38,000 after buying an additional 297 shares during the period. Quent Capital LLC purchased a new stake in shares of Jazz Pharmaceuticals during the third quarter worth about $44,000. Geneos Wealth Management Inc. raised its holdings in shares of Jazz Pharmaceuticals by 57.6% during the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 137 shares during the last quarter. Finally, GAMMA Investing LLC raised its stake in Jazz Pharmaceuticals by 30.7% in the 3rd quarter. GAMMA Investing LLC now owns 655 shares of the specialty pharmaceutical company’s stock valued at $86,000 after purchasing an additional 154 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Trading Up 1.4%

Shares of Jazz Pharmaceuticals stock opened at $165.50 on Friday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.44 and a current ratio of 1.65. The company has a market capitalization of $10.06 billion, a P/E ratio of -27.27, a PEG ratio of 0.89 and a beta of 0.26. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $182.99. The company’s fifty day moving average is $167.86 and its two-hundred day moving average is $145.52.

Wall Street Analysts Forecast Growth

A number of analysts have commented on JAZZ shares. TD Cowen reiterated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Thursday, January 29th. Truist Financial boosted their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a report on Monday, January 12th. Piper Sandler restated an “overweight” rating and set a $219.00 price target (up from $147.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, December 10th. JPMorgan Chase & Co. lowered their price objective on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a research note on Monday, October 27th. Finally, Bank of America lifted their target price on Jazz Pharmaceuticals from $230.00 to $247.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Fourteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $205.67.

Insider Transactions at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 77,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 26th. The stock was sold at an average price of $177.81, for a total value of $13,780,275.00. Following the transaction, the director owned 393,332 shares of the company’s stock, valued at approximately $69,938,362.92. The trade was a 16.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Patricia Carr sold 5,319 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $182.06, for a total transaction of $968,377.14. Following the completion of the transaction, the chief accounting officer owned 7,012 shares in the company, valued at approximately $1,276,604.72. This trade represents a 43.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 123,791 shares of company stock worth $21,991,850 over the last three months. 4.30% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.